Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
214 studies found for:    "Hairy cell leukemia"
Show Display Options
RSS Create an RSS feed from your search for:
"Hairy cell leukemia"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Therapy Optimisation for the Treatment of Hairy Cell Leukemia
Condition: Hairy Cell Leukemia
Intervention: Drug: Cladribine s.c. injection, HCL treatment
2 Terminated
Has Results
Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia
Condition: Hairy Cell Leukemia
Intervention: Drug: BL22 (CAT-3888)
3 Active, not recruiting LMB-2 to Treat Hairy Cell Leukemia
Condition: Hairy Cell Leukemia
Intervention: Drug: Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin
4 Recruiting Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia
Condition: Hairy Cell Leukemia
Interventions: Drug: Cladribine;   Drug: Rituximab
5 Completed Rituximab in Hairy Cell Leukemia: a Multicenter Retrospective Study
Condition: Hairy-cell Leukemia
Intervention: Other: Data collection
6 Recruiting Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
Condition: Hairy Cell Leukemia
Interventions: Drug: Pentostatin;   Drug: Rituximab;   Drug: Bendamustine
7 Completed A Phase II Efficacy Study of Roferon-A in Hairy Cell Leukemia
Condition: Hairy Cell Leukemia
Intervention: Drug: Roferon-A
8 Active, not recruiting BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia
Condition: Hairy Cell Leukemia
Intervention: Drug: Vemurafenib
9 Recruiting Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia
Conditions: Hairy Cell Leukemia;   Hairy Cell Leukemia Variant
Interventions: Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
10 Completed Treatment of Hairy Cell Leukaemia Variant and Relapsing Hairy Cell Leukaemia With Cladribine Plus Rituximab
Condition: Hairy Cell Leukemia (HCL)
Intervention: Drug: 2CdA +/- Rituximab
11 Completed A Phase I, Multicenter Dose Escalation Study in Patients With Leukemia
Condition: Hairy Cell Leukemia
Intervention: Biological: CAT 8015 (Moxetumomab Pasudotox)
12 Completed BL22 Immunotoxin in Treating Patients Previously Treated With Cladribine for Hairy Cell Leukemia
Condition: Leukemia
Intervention: Drug: BL22
13 Completed Analysis of Blood and Bone Marrow to Detect Residual Disease in Patients With Previously Treated Hairy Cell Leukemia
Condition: Leukemia
Interventions: Genetic: polymerase chain reaction;   Other: flow cytometry;   Other: immunohistochemistry staining method
14 Completed Rituximab in Treating Patients With Refractory or Recurrent Hairy Cell Leukemia Following Cladribine Therapy
Condition: Leukemia
Intervention: Biological: rituximab
15 Completed Daily or Weekly Cladribine in Treating Patients With Hairy Cell Leukemia
Condition: Leukemia
Interventions: Drug: 2-chlorodeoxyadenosine (CDA) daily;   Drug: 2-chlorodeoxyadenosine weekly
16 Recruiting 2CDA With Rituximab in Hairy Cell Leukemia
Condition: Leukemia
Interventions: Drug: Cladribine;   Drug: Rituximab
17 Unknown  Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease
Conditions: Leukemia;   Hairy Cell Leukemia;   HCL
Interventions: Drug: Immunotoxin therapy;   Drug: CAT-8015 Immunotoxin;   Procedure: Biological therapy
18 Active, not recruiting Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia
Condition: Leukemia, Hairy Cell
Interventions: Drug: moxetumomab pasudotox;   Drug: IV Bag Protectant for Moxetumomab pasudotox
19 Recruiting Clinical Research in Hairy Cell Leukemia:Surveillance and Documentation of Clinical Outcomes
Condition: Leukemia, Other
Intervention:
20 Unknown  Assessment of the V600E Mutation in the B-RAF Gene in Chronic Lymphoproliferative Disease
Conditions: Hairy Cell Leukemia;   Splenic Marginal Zone Lymphoma
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.